However, our and others’ data corroborate the hypothesis that TNF‐α is a possible novel therapeutic option for GBM patients and future clinical studies should be aimed at inhibiting TNF‐α as a concurrent immunotherapy in GBMs. Here, TNF is linked to glioblastoma.